In part I published in 2018, we introduced the SPIRAL model. It proposes that cross-reactivity is the basic unit that drives the evolution of adaptive immune system and it is thymus-derived regulatory T cells, Tregs, that rely on cross-reactive epitopes to control other T cells
We also proposed that thymus-derived #Foxp3 Tregs rely on #CrossReactive epitope derived from the friendly gut microbiota to survive and function in the periphery. So one of the main roles of gut microflora is to supply #Tregs with epitopes.
when we lose good microflora we lose the corresponding epitope-specific thymus-derived Tregs and that induces both allergies and autoimmunity but only if antigens that induce allergy or autoimmunity are cross-reactive.
in part II, we tackled the question of the origin of thymus-derived Tregs. They need epitopes from friendly microbiota, but Tregs need IL-2 too. Where is this IL-2 coming from and how? #CrossReactivity provided the answer here too.
We proposed that IL-2 is derived from T cells that express TCR that recognize similar epitopes as Tregs. In essence, each Treg clone has its own 'partner' IL-2-producing T cells that they exist in dyads, a functional unit, necessary for Treg survival.
Basically, Tregs need both microbiota-derived epitopes and IL-2 derived from T cells sharing TCR cross-reactivity. It is these IL-2-producing T cells that drive pathologies when we lose microbiota and lose Tregs.
in this, concluding part III of the SPIRAL model, we asked what is so special about these IL-2 producing T cells? We proposed that these IL-2 producing T cells that normally act as Treg 'partners' are in fact memory T cells and source of all pathological T helper polarizations.
In immunology, T helper differentiation and T helper polarization are used interchangeably. However, these are two different phenomena. T helper differentiation is a physiological process driven by the innate system from naive T cells while T helper polarization is a pathology &
requires the presence of #CrossReactive memory T cells. The innate signaling alone cannot induce T helper polarization.
The polarized T helper response is a source of immune pathology such as allergies, ineffective immune response to pathogens. All these require #CrossReactivity and loss of Treg/microbiota axis.
why do we have allergies? there is nothing special about allergen except is it recognized by cross-reactive, pre-existing memory T cells and there is loss of 'partner' Treg/microbiota axis to keep them in check.
what is an ineffective immune response to pathogens? it is when a new pathogen re-activates pre-existing memory T cells via cross-reactivity and there is no 'partner' Treg/microbiota axis to stop it from polarization and inhibiting other naive T cells. #OriginalAntigenicSin
properly functioning adaptive immune system needs the full house of Tregs that relies on microbiota-derived epitopes and IL-2 produced by 'partner' memory T cells. It all depends on epitope #CrossReactivity.
These two graphs tells the story about 3rd wave with #DeltaVariant.
daily cases vs. daily death. Based on data from 2nd wave,we should have expected already ~ 500-2000 death daily but so far the UK only reported ~ 100 daily death. Does it mean vaccine worked? No. why not?
1/
Why cannot I say with certainty that 10-20 fold lower daily deaths in the 3rd wave indicate that the vaccine is effective?
Simply because the authority consistently say that >90% of those who are diagnosed with #COVID19 are non-vaccinated.
2/
So, >90% with #COVID19 are non-vaccinated and still there is 10-20 fold fewer daily death?
This makes no sense unless #COVID19 positive population in 3rd wave is completely different from those in the 1st and 2nd waves.
3/
We are entering a new, endemic stage of #COVID19 spread. Drop in efficacy (50% or less) against new SA variants is a classical example of vaccine efficacy against #influenza virus.
It is clear from all available data that both @BioNTech_Group and @moderna_tx mRNA vaccines will be less effective against SA variant and there will be many more like this.
@RMedzhitov Why focus on allergy? b/c allergy is a paradox. The allergy we recognize is a completely maladaptive response and has no protective role whatsoever. It is not clear why do we even need IgE
2/
@RMedzhitov So, some 10 years ago or so, @RMedzhitov started to suggest that #allergy is an intrinsic property of a certain type of #antigens, many of them with enzymatic function (enzymes). 3/
1st, there is no standard threshold above which something is called #CytokineStorm.
Mechanistically, the simplest form of #CytokineStorm we can understand is when anti-CD19 #CART cells are infused in tumor-bearing recipients.
in this scenario, we have large numbers of antigen-specific T cells (anti-CD19) and large numbers of antigen-bearing cells (CD19+ tumor cells). When too many T cells engage with too many antigens simultaneously in a short period of time we get #CytokineStorm
Why is that? This is because naturally developing an adaptive immune system (T cells) ordinarily doesn't work that way. 1st, for a given antigen we have very few antigen-specific T cells (~ 50 cells/antigen, unlike anti-CD19 CAR-T cells that are in millions).
a removal of a subset of #Tregs called T follicular regulatory cells (Tfr) from the immune system in #Foxp3-cre Bcl6-fl/fl mice #paradoxically reduces, rather than increases, #peanut-specific #IgE responses.
And if you think maybe their knockout mice are some kind of weirdos, not really. Their model also shows that total IgE is increasing as expected. So, the system the authors are using is within acceptable norms.
The authors then went on to show that IL-10 derived from Tfr cells are important for promoting peanut allergy-producing IgE production. (IL-10 is lesser understood cytokine but it is generally accepted as an immunosuppressant.) #immunology
#Antibody response usually protects against infection/re-infection but #Tcells could protect against clinical signs of disease. #COVID19
The paper from #1990 analyzed the antibody response and clinical symptoms of the common cold #coronavirus#229E. Neutralizing antibody titers declined within 1 year after 1st challenge, and 70% from the "immunized" cohort got re-infected but none showed clinical symptoms.
This most likely explanation is that clinical symptoms were controlled by virus-specific T cells. There is an assumption here that a protective level of antibody would have prevented re-infection in the first plays